- Published: Tuesday April 4 2017 10: 30
Ipsen Monday finalized the acquisition of Onivyde, flagship of the US biotech Merrimack Pharmaceuticals already indicated in metastatic pancreatic cancer, for which the French drugmaker would pay up to one billion dollars in total.
Financial terms of the transaction, which was announced in early January, include an upfront payment from Ipsen 575 million in Merrimack.
To this amount could be added later to 450 million dollars, "subject to the approval of potential new indications of Onivyde the United States," recalls Ipsen in a statement.
Ipsen has granted exclusive marketing rights for current indications and future Onivyde the United States, as well as effective with Shire licensing agreements for sales outside the US, and with PharmaEngine company in Taiwan.
About 338.000 people are diagnosed with pancreatic cancer each year worldwide, of which about 50.000 in the United States. More than half of these cases are diagnosed in metastatic (advanced).
This is the 3e cause of death related to cancer in the United States, ahead of breast cancer, according to Ipsen.
In January the CEO of Ipsen, David Meek, had banked on a Onivyde sales peak in the United States than 300 million for the only existing indication of metastatic pancreatic cancer.
Ipsen will be responsible for the further clinical development of Onivyde in other indications: first-line pancreatic cancer, lung cancer and breast cancer.
This complete treatment already well stocked Ipsen's pipeline in oncology, where the group is already present in the treatment of neuroendocrine tumors, prostate cancer, kidney and bladder.